Interestingly, EVO treatment has been shown to suppress IFN-γ-induced PD-L1 expression in non-small-cell lung cancer cells, reduce T-cell apoptosis, and enhance CD8+ T-cell infiltration in vivo in a Lewis lung carcinoma model 52, suggesting a potential anti-cancer strategy through combination therapy with EVO and anti-PD-1 mAb. Here, CD8A is linked to cancer.